Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

No reported Net Margin figures are available to summarize.

Net Margin history

Percent of revenue · from the income statement

No Net Margin data reported for this period type.

Net Margin vs competitors

How TRVI compares with its peers on the latest reported figures

TRVI Competitors Peer median
Net Margin for TRVI and competitors
Company Period LTM level YoY 3-year change
TBPHTheravance Biopharma, Inc.LTM Mar 2026104.3% +193.7 pp-1600.0 pp
LQDALiquidia CorporationLTM Jun 202630.7% +762.9 pp+213.9 pp
ACADACADIA Pharmaceuticals Inc.LTM Sep 202630.1% +5.2 pp+78.2 pp
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-37.5% +530.6 pp+73239.9 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-536.4% ——
UPBUpstream Bio, Inc.LTM Mar 2026-4719.0% -1270.3 pp-3056.7 pp
VCREVicore Pharma Holding ABLTM Jun 2026-20489.5% -11011.9 pp—
TRVITrevi Therapeutics, Inc.FY2025— ——
TENXTenax Therapeutics, Inc.FY2025— ——
Peer median (excluding TRVI) -37.5%+99.5 pp+78.2 pp

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development22.98M19.83M23.68M39.38M33.48M
Selling, General & Admin9.49M10.07M10.24M12.15M15.85M
Operating Expenses32.48M29.91M33.92M51.52M49.33M
Depreciation & Amortization50K43K123K147K144K
EBITDA(32.71M)(27.98M)(28.58M)(47.79M)(42.68M)
EBITDA Margin—————
Operating Income(32.48M)(29.91M)(33.92M)(51.52M)(49.33M)
Operating Margin—————
Interest Income10K1.74M4.75M3.6M6.54M
Interest Expense1.2M780K391K4K0
Other Income / Expenses(1.49M)719K4.83M3.58M6.51M
Income Before Tax(33.96M)(29.19M)(29.1M)(47.94M)(42.82M)
Pre-Tax Margin—————
Income Tax Expense(21K)(36K)(32K)(30K)(64K)
Net Income(33.94M)(29.15M)(29.07M)(47.91M)(42.76M)
Net Margin—————
EPS (Basic)(1.49)(0.45)(0.29)(0.47)(0.29)
EPS (Diluted)(1.49)(0.45)(0.29)(0.47)(0.29)
Weighted Avg Shares22.84M64.54M99.03M101.04M145.1M
Weighted Avg Shares (Diluted)22.84M64.54M99.03M101.04M145.1M

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.